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Rapport de synthèse 
Le récepteur activé par protéase de type 2 (PAR2) intervient dans l'infla:plmation dans 
divers modèles expérimentaux de maladies inflammatoires et auto-immunes, mais le 
mécanisme par lequel il exerce cette fonction reste mal compris. P AR2 est exprimé sur 
des cellules endothéliales et immunitaires et a été impliqué dans la différentiation des 
cellules dendritiques (DC). Avec leur rôle central dans la réponse immune, les DC 
pourraient jouer un rôle clef, l'activation de PAR2 à leur surface modulant la réponse 
immune. Des recherches précédentes ont montré que P AR2 a un effet dans le 
développement et la maturation des DC de moelle osseuse in vitro, ainsi que dans la 
promotion de la réponse immune en allergie. 
Dans cette étude, nous avons évalué l'impact in vivo de l'activation de PAR2 sur les 
DC et les cellules T dans des souris déficientes en PAR2 (KO) en utilisant un peptide 
agoniste spécifique du PAR2 (AP2). L'activation de PAR2 a augmenté la fréquence 
de DC matures dans les ganglions lymphatiques 24 heures après l'administration 
d' AP2 d'une manière significative. En outre, ces DC avaient une expression 
augmentée des molécules de co-stimulation CD86 et du complexe majeur 
d'histocompatibilité type 2 (MHC-II). 48 heures après l'injection d' AP2, nous avons 
également observé une élévation significative des lymphocytes T CD4+ et CD8+ 
activés, (CD44+CD62-) dans ces ganglions. Des changements dans le profil 
d'activation des DC et des cellules T n'ont pas été observés au niveau de a rate. 
L'influence de la signalisation de PAR2 sur le transport d'antigène aux ganglions 
lymphatiques inguinaux a été évaluée dans le contexte d'hypersensibilité retardée de 
type IV, Les souris KO sensibilisées par peinture de la peau avec fluorescéine iso-
thyocyanate (FITC) afin d'induire une hypersensibilité retardée avaient un 
pourcentage diminué de DC FITC+ dans les ganglions lymphatiques 24 heures après 
l'application du FITC en comparaison avec les souris sauvages avec le même fond 
génétique (0.47% vs 0.95% des cellules ganglionnaires totales). 
En conclusion, ces résultats démontrent que la signalisation de P AR2 favorise et 
renforce la maturation et le transport d'antigène par des DC vers les ganglions 
lymphatiques ainsi que l'activation ultérieure des lymphocytes T, et de ce fait 
fournissent une explication pour l'effet pro inflammatoire de PAR2 dans les modèles 
animaux d'inflammation. Une meilleure compréhension de ce mécanisme de 
modulation du système immun via P AR2 peut s'avérer particulièrement utile pour le 
développement des vaccins, ainsi que pour la découverte de nouvelles cibles 
, thérapeutiques dans le contexte de l'allergie, l'auto-immunité, et les maladies 
inflammatoires. 
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Introduction 
Surnrnary 
Deficiency of protease-activated receptor-2 (PAR2) modulates inflamma-
tion in several models of inflammatory and autoimmune disease, although 
the underlying mechanism(s) are not understood. PAR2 is expressed on 
endothelial and immune cells, and is implicated in dendritic cell (DC) dif-
ferentiation. W e investigated in vivo the impact of P AR2 activation on 
DCs and T cells in PAR2 wild-type (WT) and knockout (KO) mice using 
a specific PAR2 agonist peptide (AP2). PAR2 activation significantly 
increased the frequency of mature CDllchigh DCs in draining lymph 
nodes 24 hr after AP2 administration. Furthermore, these DCs exhibited 
increased expression of major histocompatibility complex (MHC) class II 
and CD86. A significant increase in activated (CD44+ .CD62-) CD4+ and 
CDS+ T-cell frequencies was also observed in draining lymph nodes 48 hr 
after AP2 injection. No detectable change in DC or T-cell activation pro-
files was observed in the spleen. The influence of PAR2 signalling on anti-
gen transport to draining lymph nodes was assessed in the context of 
delayed-type hypersensitivity. PAR2 WT mice that were sensitized by 
skin-painting with fluorescein isothiocyanate (FITC) to induce · delayed-
type hypersensitivity possessed elevated proportion of FITC+ DCs in 
draining lymph nodes 24 hr after FITC painting when compared with 
PAR2 KO mice (0·95% versus 0·47% of total lymph node cells). Collec-
tively, these results demonstrate that P AR2 signalling promotes DC 
trafficking to the lymph nodes and subsequent T-cell activation, and thus 
provides an explanation for the pro-inflammatory effect of P AR2 in 
animal models of inflammation. 
Keywords: AP2; dendritic cells (DCs); protease-activated receptor-2 
(PAR2); T cells 
The protease-activated receptor-2 (PAR2) has been impli-
cated in the pathogenesis of seveial inflammatory and 
autoimmune disorders, 1- 10 and is expressed in a wide 
variety of human tissues and cells. 11- 15 PAR2 knockout 
(KO) mice are relatively resistant to inflammation16 and 
P AR2 has been shown to affect multiple aspects of the 
tissue response to injury and inflammation.17 The under-
lying cellular mechanisms remain unclear. 
ated cell-signalling cascade19'20 and nuclear factor-kappa 
B (NF-KB)-regulated gene transcription.21- 23 Serine prote-
ases such as thrombin, trypsin, neutrophil proteinase-.3 
(PR3) and mast cell tryptase, as well as coagulation fac-
tors Vila and Xa, have been shown to activate PAR2.24- 28 
Physiopathologically, P AR2 can be activated during 
injury, inflammation or atopy.27 Experimentally, PAR2 
can also be activated using a synthetic agonist hexa-
peptide, SLIGRL (AP2), which emulates the tethered 
ligand without the need for proteolysis.28-31 In this study 
we used an AP2 peptide modified by replacement of the 
N-terminal serine with a 2-furoyl group and a C-terminal 
ornithine (2-furoyl-LIGRLO), as this peptide represents 
the most patent, selective and metabolically stable (lon-
gest half-life) PAR2 agonist peptide available.32'33 
P AR2 belongs to a family of seven transmembrane 
domain receptor proteins that are activated by proteolysis. 
Enzymatic digestion exposes an N-terminus ligand 
sequence that binds intramolecularly to the activation site 
on the extracellular loop II, 18 initiating a G-protein-medi-
20 © 2009 Blackwell Publishing Ltd, lmmuno/ogy, 129, 20-27 
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P AR2 expression on leucocytes has been reported but 
not well characterized.9' 10 In a recent human study, imma-
ture monocyte-derived DCs (MoDCs) were shown to 
differentiate to a mature phenotype in the presence of PR3. 
Furthermore, by blocking the protease activity of PR3 with 
a serine protease inhibitor, dendritic cell (DC) maturation 
was inhibited.34 DCs are critical orchestrators of the 
immune system and provide a link between innate and 
adaptive immunity. Acting as professional antigen-present-
ing cells (APCs), DCs sample and process antigen in 
peripheral tissues and transport it to secondary lymphoid 
organs, mainly the lymph node, where they activate T cells 
and modulate the acquired immune response.35 Danger 
signais act on DC innate immune receptors to induce 
acquired immunity. The best known of these receptors are 
the toll-like receptors (TLRs) that .can activate DCs and 
stimulate their differentiation from haematopoietic pro-
genitors.36 Moreover, TLR4 and PAR2 have been recently 
reported to cooperate and exert synergistic pro-inflamma-
tory effects.37 
In this study, we investigated the in vivo effects of P AR2 
activation on DCs and T cells using AP2 as a P AR2 ligand 
and compared the effects observed in PAR2 KO and wild-
type (WT) mice. Our results showed that P AR2 signalling 
leads to an enhanced state of DC and T-cell activation that 
could account for the observed contribution of PAR2 in 
immune-mediated inflammatory disorders. 
Materials and methods 
Animais 
PAR2 KO (B6 background) mice were a gift of Dr S. 
Coughlin. 16 PAR2 KO and WT littermates, S-12 weeks of 
age, were used in the experiments. Mice were anaesthe-
tized with inhaled isoflurane and then killed by cervical 
dislocation. Institutional approval was obtained for all 
animal experiments. 
Agonist peptide 
The synthetic agonist peptide 2-furoyl-LIGRLO-amide 
(AP2) (Bachem AG, Bubendorf, Switzerland) was sus-
pended in sterile phosphate-buffered saline (PBS). For 
in vivo studies, AP2 was administrated as an intraperitoneal 
(i.p.) injection at 1 µM/kg. 38 
Cell preparation 
Single-cell suspensions from harvested spleen and lymph 
nodes were prepared by incubating ·organs for 25 min at 
25° in 1 mg/ml of collagenase D (Roche, Penzberg, 
Germany) + 105 µg/ml of DNAse I (Roche) in RPMI 
medium (Invitrogen, Basel, Switzerland) supplemented 
with 50 U/ml of penicillin, 50 µg/rnl of streptomycin and 
© 2009 Blackwell Publishing Ltd, lmmunology, 129, 20-27 
5% fetal calf serum (FCS) (Sigma-Aldrich, Buchs, Switzer-
land) and then filtered through a 40-µm nylon cell strai-
ner. Cells were subsequently washed twice with 
supplemented RPMI medium. Viable cell counts were 
performed using Trypan Blue. 
Fluorescein isothiocyanate painting 
Mice were shaved 1 day before fluorescein isothiocyanate 
(FITC) painting. FITC powder (Sigma-Aldrich) was dis-
solved in a 50 : 50 (v/v) mixture of acetone and dibu-
tylphthalate to obtain a O·So/o FITC solution. FITC 
solution (20 µl) was applied onto the abdominal skin of 
mice, and 24 hr later antigen-draining inguinal lymph 
nodes were harvested and digested with collagenase 
solution, as described above, before analysis was 
performed. 
Flow cytometry 
Cells were suspended in fluorescence-activated cell sorter 
(FACS) buffer (3% FCS, 5 mM EDTA in PBS). Cells were 
incubated with conjugated monoclonal antibodies (mAbs) 
in the presence of Fe blockers. All data acquisition was per-
formed on a FACScanto™ flow cytometer (Becton-Dickin-
son, San Jose, CA). The mAbs used (Becton-Dickinson) 
were: CDllc-phycoerythrin Cy7 (PECy7), CDllc-phyco-
erythrin (PE), major histocompatibility complex (MHC) 
class II-PE, MHC class II-FITC, B220-PECy7, B220-allophy-
cocyanin Cy7 (APCCy7), B220-FITC, CDllb-PE, CDllb-
allophycocyanin, CDSO-phycoerythrin Cys (PECyS), 
CD40-allophycocyanin, CDS6-allophycocyanin, CDSa-phy-
coe1ythrin CyS.5 (PECyS.5), CDSa-PECy7, CDSa-FITC, 
CD4-FITC, CD4-APCCy7, CD24-FITC, CD3-PECy5.5, 
CD44-allophycocyanin and CD62L-FITC. 
The DC subpopulation analysed included plasmocytoid 
(CDllc+, CDllb-, CDSa+1-, B220+) and conventional 
(CDllc+, CDllb+, CDSa-, B220- and CDllc\ CDllb-, 
CDSa +, B220-) DCs, as well as CD l lchigh total DCs. 
MHC class II, CD40, CDSO and CDS6 expression served 
as indicators for DC maturation. T cells were indentified 
as CD3+ and either CD4+, CDS- (for CD4 T cells) or 
CD4-, CDS+ (for CDS+ T cells). CD44 and CD62L 
expression were used to assess the T-cell activation status. 
Statistical analysis 
All values were expressed as the mean ± standard error of 
the rnean (SEM). Variation between data sets was evalu-
ated using the Student's t-test of unpaired data for AP2 
experiments and the paired t-test for the FITC painting 
experiments, with a 95% confidence interval. A P value of 
< 0·05 was considered statistically significant. Data were 
analysed using GRAPHPAD PRISM software (GraphpPad Soft-
ware, La Jolla, CA). 
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Results 
We initially analysed different DC subset frequencies in 
lymph nodes of naive P AR2 WT and KO mice to deter-
mine the contribution of P AR2 to DC development and 
trafficking under steady-state conditions. DC proportions 
were comparable between naive P AR2 WT and KO mice 
(Table 1), indicating that the absence of P AR2 does not 
Table 1. Inguinal lyrnph node dendritic cell (DC) subset frequencies 
present in naive protease-activated receptor-2 (PAR2) wild-type 
(WT) and knockout (KO) mice 
WT KO 
CDllc+ B220- 1·365 ± 0·04455 1·235 ± 0·06941 
(cDC, % of total cells) 
CDllc+ B220- CDllb+ CD8a- 66·00 ± 1·900 63·05 ± 6·450 
(%of cDC) 
CD!lc+ B220- CDllb- CD8a+ 15·03 ± 1·021 16·88 ± 2·581 
(%of cDC) 
CDllc+ B220+ 0·4200 ± 0·1348 0·5400 ± 0·1991 
(pDC, % of total cells) 
Values represent mean values ± standard error of the mean (SEM). 
For ail groups, n = 6. 
cDC, conventional DC; pDC, plasmoctoid DC. 
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grossly impact on DC development and homing to sec-
ondary lymphoid organs under non-inflammatory condi-
tions. To confirm that PAR2 deficiency has no influence 
on DC development, we next investigated whether there 
are differences in bone marrow-derived dendritic cell 
(BMDC) formation capacity between P AR2 KO and WT 
bone marrow precursors in vitro. When cultured in the 
presence of granulocyte-monocyte colony-stimulating fac-
tor (GM-CSF), no significant differences were observed in 
the generation of BMDC from P AR2 WT and KO bone 
marrow-derived progenitors (data not shown). 
In order to determine the contribution of PAR2 activa-
tion to DC maturation and trafficking to secondary lym-
phoid organs, we utilized a P AR2 agonist peptide (AP2) 
to activa te P AR2 in vivo. A single dose of AP2 was 
administered to PAR2 WT and KO mice and, 24 hr later, 
the DC frequencies in draining lymph nodes were 
assessed. Our analyses revealed an increased frequency of 
CDllchigh cells in PAR2 WT mice 24 hr after AP2 injec-
tion when compared with similarly treated PAR2 KO or 
PBS-injected WT mice (Fig. la,b). To understand in more 
detail the impact of P AR2 activation on DC maturation 
kinetics, a time-course experiment was set up. Draining 
inguinal lymph node CDllchigh DCs were analysed from 
PAR2 WT mice at 12, 24, 48, 72 and 96 hr following a 
single AP2 injection. Mice injected with PBS only served 
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Figure 1. (a) Inguinal lyrnph node MHC+ CDllchigh dendritic cell (DC) numbers from protease-activated receptor-2 (PAR2) wild-type (WT) 
and knockout (KO) mice 24 hr following intraperitoneal (i.p.) injection with 1 ~tM/kg of AP2 or with phosphate-buffered saline (PBS). Plots are 
representative of four mice per group. MHC II, major histocompatibility complex class II. (b) Inguinal lyrnph node CDllchigh DC numbers from 
PAR2 · WT and KO mice 24 hr follo-iving i.p. injection with 1 µM/kg of AP2 or with PBS. For ail groups, n = 4. Error bars represent mean 
values± standard error of the mean (SEM). For P values: *P < 0·05. (c) Kinetics of CDllchigh DCs in draining inguinal lymph nodes after a 
single AP2 dose (left) and 96 hr after daily i.p. injections with 1 ~tM/kg of AP2 (right). Data are expressed as the percentage of total lymph node 
cells. Error bars represent mean values ± SEM. For the 0-, 24- and 48-hr groups, n ·= 7; for the 12- and 72-hr groups, n = 4; and for the 96-hr 
and daily injection (for 96 hr) groups, n = 3. Data were pooled from two independent experiments. For P values: *P < 0·05, **P < 0·01, 
***P < 0·001 and NS, not statistically significant. 
22 © 2009 Blackwell Publishing Ltd, lmmunology, 129, 20-27 
5of10 
PAR2 signalling promotes DC and T-cell activation in vivo 
(a) 
§~ ·(i)~ 
gi ~120 
o.~ 10 ~ 0 
= c 80 
o-§. 
:r: E 60 
2 
.è 40 -g~ 
~~ 20 
§ Ei 0 
oü 
z~ 
(c) 
80000 
iI 
2 
=4000 
0 
:r: 
22000 
i ' .•••• i ' ' ' O 1224364860728496108 96(daily) 
Length of lime alter AP2 injection (hr) 
* (·······-··------·~-'a 
KO AP2 WT AP2 WT PBS 
(b) 
c~ 
0"' ·~ !120 , .. :!:~., 
!f~o )\~.$., ... ~ ... ~ 
~J :~ , ........ L ..... ., 
1JEo 20 _.Âl 
"'~ . § Ei 0 
~ S?.. 0 1224364860728496108 ~ 
(d) 
2000 
1500 
iI 
2 
<01000 
<O 
a 
0 
500 
Length of lime alter AP2 injection (hr) 
Figure 2. (a) Kinetics of major histocompatibility complex (MHC) class II expression on dendritic cells (DCs) from inguinal lymph nodes after a 
single 1 µM/kg dose of AP2 (left) and at 96 br after daily intraperitoneal (i.p.) injections of 1 µM/kg of AP2 (right). Data were pooled from two 
independent experiments and are expressed as a percentage of the highest geometric mean of MHC class II fluorescence. Error bars represent the 
mean values ± standard error of the mean (SEM). For the 0-, 24- and 48-hr groups, 11 = 7; for the 12- and 72-hr groups, 11 = 4; and for the 
96-hr and daily injection (for 96 hr) groups, n = 3 .. For P values: *P < 0·05, **P < 0·01. (b) Kinetics of CD86 expression on DCs from inguinal 
lymph nodes after a single 1 µM/kg AP2 dose (left) and at 96 hr after daily i.p. injections with 1 µM/kg of AP2 (right). Data were pooled from 
two independent experitnents and are expressed as a percentage of the highest geometric mean of CD86 fluorescence. Error bars represent mean 
values ± standard error of the mean (SEM). For the 0-, 24- and 48-hr groups, 11 = 7; for the 12- and 72-hr groups, 11 = 4; and for the 96-hr and 
daily injection (for 96 hr) groups, 11 = 3. For P values: *P < 0·05, **P < 0·01 and NS, not statistically significant. (c) MHC class II expression 
(geometric mean of fluorescence) on protease-activated receptor-2 (PAR2) wild-type (WT) and knockout (KO) DCs from inguinal lymph nodes 
24 hr after a single i.p. injection with 1 ~tM/kg of AP2 or phosphate-buffered saline (PBS). Plots are representative of four mice per group. Error 
bars represent the mean values± SEM. For P values: *P < 0·05. (d) CD86 expression (geometric mean of fluorescence) on PAR2 WT and KO 
DCs from inguinal lymph nodes 24 br after a single i.p. injection with 1 ~tM/kg of AP2 or PBS. Plots are representative of four mice per group. 
Error bars represent mean values ± SEM. 
as negative contrals for DC analysis. CDllchigh DC num-
bers peaked in inguinal lymph nodes 24 hr after adminis-
tration of AP2 before gradually returning to baseline 
levels (Fig. le). To assess the influence of AP2 on DC 
activation and differentiation, the expression of MHC 
class II and of CDS6 were characterized on lymph node 
CDllehigh DCs at the various time-points. In AP2-treated 
mice, DCs significantly up-regulated MHC class II 
(Fig. 2a) and CDS6 (Fig. 2b) on their cell surface, with 
peak expression observed 24 hr after AP2 administration. 
After 24 hr, expression of these markers returned to basal 
levels. Daily administration of AP2 did not significantly 
increase DC numbers (Fig. le) at the 96 hr time-point, 
but they expressed higher levels of MHC class II and 
CDS6 (Fig. 2a,b respectively), No consistent differences 
were observed in the spleen (data not shown). 
Lymph node CD4+ and CDS+ T cells were also charae--
terized for expression of activation markers following sin-
gle and repeated injection of AP2, as described above. 
Both CD4+ and CDS+ T cells expressed peak levels of 
CD44, a marker of mature activated T cells, 4S hr after a 
© 2009 Blackwell Publishing Ltd, /mmuno!ogy, 129, 20-27 
single AP2 injection (Figs 3c and 4c), followed by a 
return to basal levels thereafter. After repeated daily 
administration of AP2, the expression of CD44 on T cells 
did not increase above basal levels (Figs 3c and 4c). No 
consistent differences were detected in the spleen (data 
not shown). 
In order to show that the AP2-mediated effects on DCs 
and T cells were PAR2 specific, we praceeded to compare 
the impact of AP2-treated P AR2 WT mice ( designated 
WT AP2), PAR2 WT mice receiving PBS alone (WT PBS) 
and PAR2 KO mice injected with AP2 (KO AP2). WT 
AP2 DCs expressed significantly higher levels of MHC 
class II compared with WT PBS DCs. CDS6 expression 
on WT AP2 was also higher compared with contrais, but 
did not reach significance (Fig. 2c,d). As for T cells, WT 
AP2 showed a twofold increase of CD44high and 
CD44+ CD62L -, CD4+ and CDS+ T cells compared with 
both contrais (Figs 3a and 4a). CD4+ T cells displaying 
an activated phenotype (CD3+ CD4+ CD44high CD62L-) 
were more praminent in the draining lymph node of the 
WT AP2 graup when compared with contrai graups 
23 
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Figure 3. (a) CD4+ T-cell activation in the inguinal lymph nodes of protease-activated receptor-2 (PAR2) wild-type (WT) and knockout (KO) 
mice 4S hr after a single intraperitoneal (i.p.) injection with 1 µM/kg of AP2 or phosphate-buffered saline (PBS). CD3+ CD4+ CDS- gated cells 
were analysed for CD44 (y axis) and CD62 (x axis) expression. Plots are representative of three mice per group. (b) Activated PAR2 WT and KO 
CD4+ T cells (CD3+ CD4+ CDS-CD44'' CD62L-) in inguinal lymph nodes 4S hr after a single i.p. injection with 1 µM/kg of AP2 or PBS. For ail 
groups, 11 = 3. Error bars represent mean values ±standard error of the mean (SEM). For P values: *P < 0·05. (c) Kinetics of CD44 expression 
in CD4+ T cells from inguinal lymph nodes after a single 1 µM/kg AP2 dose (left) and 96 hr after daily i.p. injections with 1 µM/kg of AP2 
(right). Data were pooled from two independent experiments and are expressed as a percentage of the highest geometric mean o\ CD44 fluores-
cence. Error bars represent the. mean values ± SEM. For the 0-, 24- and 4S-hr groups, n = 7; for the 12- and 72-hr groups, n = 4; and for the 
96-hr and daily injection (for 96 hr) groups, n = 3. For P values: **P < 0·01, ***P < 0·001 and NS, not statistically significant. 
(a) KOAP2 
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Figure 4. (a) CDS+ T-cell activation in the inguinal lymph nodes of protease-activated receptor-2 (PAR2) wild-type (WT) and knockout (KO) 
mice 4S hr after a single intraperitoneal (i.p.) injection with 1 µM/kg of AP2 or phosphate-buffered saline (PBS). CD3+ CDS+ CDÇ gated cells 
were analysed for CD44 (y axis) and CD62 (x axis} expression. Plots are representative of three mice per group. (b) Activated PAR2 WT and KO 
CDS+ T cells (CD3+ CDS+ CD4-CD44+ CD62L-) in inguinal lymph nodes 4S hr after a single i.p. injection with 1 µM/kg of AP2 or PBS. For ail 
groups, 11 = 3. Error bars represent mean values ±standard error of the mean (SEM). For P values: *P < 0·05. (c) Kinetics of CD44 expression 
in CDS+ T cells from inguinal lymph nodes after a single 1 µM/kg AP2 dose (left) and at 96 hr after daily i.p. injection with 1 µM/kg of AP2 
(right). Data were pooled from two independent experiments and are expressed as a percentage of the highest geometric mean of CD44 fluores-
cence. Error bars represent mean values ± SEM. For the 0-, 24- and 4S-hr groups, n = 7; for the 12- and 72-hr groups, n = 4; and for the 96-hr 
and daily injection (for 96 hr) groups, n = 3. For P values: **P < 0·01, ***P < 0·001 and NS, not statistically significant. 
(Fig. 3b). A similar trend was also observed for activàted 
CDS+ T cells (CD3+ CDS+ CD44high CD62L-) in the WT 
AP2 group (Fig. 4b). These results show that PAR2 acti-
24 
vation promotes increased numbers of DCs in the drain-
ing lymph nodes as well as the expression of DC 
maturation markers. At 24 hr after the DC peak, we 
© 2009 Blackwell Publishing Ltd, lmmuno/ogy, 129, 20-27 
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Figure S. Fluorescein isothiocyanate (FITC) 
uptake and transport by CDllchigh dendritic 
cells (DCs) to inguinal lymph nodes 24 hr after 
FITC painting of the abdominal skin, FITC+ 
CDllchigh DCs were gated (left) and their 
frequency was compared between protease-
activated receptor-2 (PAR2) knockout (KO) 
and wild-type (WT) littermates (right). For all 
groups, 11 = 7. Err or bars represent mean 
values ± standard error of the mean (SEM). 
For P values: *P < 0·05. The data are represen-
tative of three independent experiments, 
0 102 103 104 105 
found evidence of lymph node T-cell activation after a 
single injection of APZ. 
W e next wanted to assess whether P AR2 signalling 
could enhance ailtigen uptake and transport by DCs, from 
the periphery to the draining lymph nodes, in an inflam-
matory context. For this purpose, FITC painting experi-
ments were performed on P ARZ WT and KO littermate 
mice, and FITC transport to the draining lymph nodes by 
DCs was comparéd. FITC has been shown to be a contact 
sensitizer that induces Type IV hypersensitivity39 and 
allows visualization of DC migration and antigen take-
up.40 At Z4 hr after FITC painting, WT mice had a higher 
proportion of Frrc+ DCs in draining lymph nodes com-
pared with P ARZ KO mice. The mean percentage of 
FITC+ DCs in the draining lymph nodes Z4 hr after FITC 
painting on the skin was 0·95% for WT mice versus 
0·47% for their KO littermate counterparts (Fig. 5). Most 
FITC-bearing DCs found in the lymph nodes had a 
CDllb+ CD8ix- phenotype (data not shown). 
Discussion 
Although an immunoregulatory role .of PAR2 in inflam-
mation· is widely acknowledged, the mechanism(s) that 
account for its influence are not well understood. With 
their central role in adaptive and innate immunity, DCs 
are strong candidates to explain how P ARZ modulates the 
immune response during inflammation. Previous reports 
have shown that P ARZ activation has an effect on BMDC 
development and maturation in vitro, and boosts acquired 
immune responses during allergy.41,42 In this study, yve 
demonstrated that P ARZ activation, in the absence of 
adjuvant or other immune stimuli, leads .to increased 
numbers of DCs bearing strengthened antigen-presenta-
tion and costimulatory potential in draining lymph nodes. 
© 2009 Blackwell Publishing Ltd, lmmuno/ogy, 129, 20-27 
FITC 
This is followed by an increase in CD4+ and cos+ T 
lymphocytes that bear markers of an effector-memory 
phenotype. W e also showed that DC capture and trans-
port of antigen from the periphery to draining lymph 
nodes following an acute inflammatory insult can be 
enhanced by P ARZ activation. 
The effect of a single systemic AP2 dose on draining 
lymph node cell populations was followed for 72 hr on 
P ARZ WT mice and was compared with WT PBS and 
KO APZ littermate control groups. The use of the highly 
selective Z-furoyl-LIGRLO-NH2 agonist peptide allowed 
us to dissect P ARZ-specific regulation of the immune sys-
tem. The mobilization of DCs to draining lymph nodes 
on day 1 and the activation of T cells within the same 
lymph nodes on day Z were the most striking P ARZ-
induced effects observed. A cause-effect relationship 
between both observations is suggested, but the cross-talk 
between DC migration and T-cell activation was not doc-
umented. The events observed might be part of a cascade 
initiated by an undetected cell type, or might be the result 
of a synergistic sum of effects. Potential AP2 targets could 
be, for example, the stromal cells of the lymph node that 
produce CCL19 and CCLZl chemokines to attract DC,43 
or the high endothelial venules (HEV) that participate in 
the regulation of DC trafficking to th,e lymph nodes.'1'1 It 
is very likely that DCs, rather than APZ, directly activate 
T cells, as Fiorucci et al~45 demonstrated that direct stim-
ulation of CD4 T cells with APZ in vitro abrogates 
induced CD44 up-regulation. Nevertheless, these results 
demonstrate that P ARZ-specific signalling promotes DC 
migration to draining lymph nodes and subsequent T-cell 
activation. In further support of these findings are the 
functional observations that APZ peptide co-administra-
tion intranasally with ovalbumin ( OV A) promotes 
OVA-mediated airways inflammation, which is associated 
25 
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with an observed increase in the proliferation of T helper 
2 (Th2) OVA-specific T cells upon OVA restimulation 
ex vivo41 and that the absence of PAR2 signalling sup-
presses myelin oligodendrocyte glycoprotein (MOG) 
induced-experimental autoimmune encephalomyelitis 
(EAE) severity in mice, which is linked with decreased 
. MOG-specific T-cell reactivity and infiltration.7 
Enhanced DC migration to draining lymph nodes is rel-
evant if this migration is accompanied by antigen capture 
in peripheral tissues and antigen transport to the lymph 
nodes for presentation to T cells. Ebeling et al.41 previ-
ously reported that artificial activation of P AR2 led to 
enhanced antigen transpo1J to the spleen in the context of 
sensitization to inhaled allerge11. Our results, from FITC. 
painting, showed that in the absence of P AR2, there is 
reduced trafficking of antigen to draining lymph nodes. 
These results imply that P AR2 activation by endogenous 
mechanisms during acute skin inflammation can enhance 
antigen transport from the skin to the draining lymph 
nodes. Topical FITC was administered in the presence of 
irritants known to induce a type IV hypersensitivity reac-
tion, but this skin irritant solution contained no proteases. 
It is known that local inflammation liberates proteases 
such as mast ce!! tryptase and PR3, enzymes that can acti-
vate P AR2 and can account for the observed increase of 
antigen-bearing DC trafficking to draining lymph nodes. 
Expression of CCR7 by P AR2-activated DCs may have led 
to increased chemotaxis to draining lymph nodes. 
Although induction of CCR7 by P AR2 has not been docu-
mented, CCR7 is known to be up-regulated during DC 
maturation. Furthermore, these DCs had migrated to 
draining lymph nodes, leading to the assumption that 
these DCs were already equipped to follow the CCL19 and 
CCL21 chemotaCtic gradient. Overall, these results show 
that P AR2 signalling can promote DC antigen transport to 
lymph nodes draining sites of inflammation. 
We failed to find a direct role for PAR2 in the differen-
tiation of BMDC (data not shown), unlike the results 
reported by Fields et al.,46 who found that PAR2-deficient 
bone marrow did not spontaneously develop BMDCs. 
Although it is possible that the addition of interleukin-4 
(IL-4) may explain the discrepancies between these 
results, we believe that the absence· of P AR2 has only a 
minor effect on the differentiation of bone marrow pro-
genitors into DCs. This hypothesis is supported by our 
findings that in naive P AR2 WT and KO mice, the DC 
frequencies in secondary lymphoid organs are equivalent. 
Although P AR2 KO mice exhibit a delayed onset of 
inflammation in most animal models, they are immuno-
competent and are able to survive in a non-specific path-
. ogen-free (SPF) environment, making a fundamental_DC 
development defect unlikely .. 
Altogether, we demonstrate that PAR2 activation pro-
motes DC maturation, antigen transport to draining lymph 
nodes and enhances lymph node T-cell activation, thus 
26 
enhancing immune activation and explaining the pheno-
type observed in animal models. A better comprehension 
of this mechanism of P AR2 immunomodulation may 
prove particularly useful for vaccine development, as well 
as hi. allergy, autoimmunity and inflammatory disease. 
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